ArticleBrain, behavior, and immunity2026
PTSD and suPAR: A multicohort investigation of chronic inflammation.
Article in Brain, behavior, and immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Soluble urokinase plasminogen activator receptor - What are the clinical potentials in psychiatry?Brain, behavior, & immunity - health · 2026Review
- From classic circuits to novel mechanisms: How lncRNA, neuroinflammation, and iPSC models address the translational crisis in PTSD research.Comprehensive psychoneuroendocrinology · 2026Review
- Interpersonal adversity and health across the life course.Current opinion in psychology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
Posttraumatic stress disorder (PTSD) is associated with poor health. Prior research has shown stressful events are associated with inflammatory biomarkers, such as soluble urokinase plasminogen activator receptor (suPAR), suggesting systemic chronic inflammation could be a mechanism linking adversity to poor health. In this study, we examined associations of PTSD and suPAR in two research cohorts-the E-Risk Study (United Kingdom; n = 1,389) and the Dunedin Multidisciplinary Health and Development Study (New Zealand; n = 927)-and a clinical cohort of medical patients (Denmark; n = 29,285). We also present results from two commonly assessed inflammatory biomarkers: C-reactive protein (CRP) and interleukin-6 (IL-6). People with a lifetime history of PTSD had higher suPAR at age 18 in E-Risk (β = 0.21, p = 0.046) and age 38 in the Dunedin Study (β = 0.23, p = 0.025), but not age 45 in the Dunedin Study (β = 0.18, p = 0.050). Individuals who developed PTSD in the year prior to age 45 in Dunedin had significant increases in suPAR from age 38 to 45 (β = 0.45, p = 0.034). Danish patients with a recent diagnosis of PTSD or a stress-related psychiatric disorder had higher levels of suPAR compared to propensity score-matched patients without such diagnoses (0.10 < βs < 0.24, ps < 0.05). CRP and IL-6 did not show consistent associations with PTSD. These results suggest that PTSD is associated with suPAR and that systemic chronic inflammation could help explain how trauma and PTSD might result in poor health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.